All In Biotech

Drug Trial Radar · NCT05490472

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors

A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-2485 in Adult Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Jan 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Dec 20, 2022

Primary completion

Aug 2026

Study completion Aug 2027

Sponsor

Sponsor type
Industry
First posted
Aug 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to evaluate the safety and tolerability of JAB-2485 monotherapy in adult participants with advanced solid tumors.

Conditions

  • Solid Tumors
  • ER+ Breast Cancer
  • Triple Negative Breast Cancer, TNBC
  • ARID1A Gene Mutation
  • Small Cell Lung Cancer, SCLC

Interventions

  • JAB-2485 (Aurora A inhibitor)Drug

    Administered orally

  • JAB-2485 (Aurora A inhibitor)Drug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation phase: Number of participants with dose limiting toxicities (DLTs)Time frame: First 21 days of Cycle 1
  2. Dose Escalation phase: Number of participants with adverse events (AEs)Time frame: Up to 3 years
  3. Dose Expansion phase: Objective Response Rate (ORR)Time frame: Up to 3 years from baseline to RECIST confirmed Progressive Disease (PD)
  4. Dose Expansion phase: Duration of Response (DOR)Time frame: Up to 3 years

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Henry Ford Health System

    Detroit, Michigan · Recruiting

  • Washington University

    St Louis, Missouri · Recruiting

  • Mary Crowley Cancer Research

    Dallas, Texas · Recruiting

  • University of Utah Huntsman Cancer Institute

    Salt Lake City, Utah · Recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Jilin Cancer Hospital

    Changchun, Jilin, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, Shandong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.